ClinicalTrials.gg
RecruitingNCT06186141POPCORNUpdated Jul 21, 2026

Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone

A Phase 4 interventional study of Morphine and Oxycodone in Patient-Controlled Analgesia, sponsored by Murdoch Childrens Research Institute. Recruiting at 1 site in Australia. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Murdoch Childrens Research Institute · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
690
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing oxycodone in Pain, Postoperative — 5 open to participants now, 7 under way, 1 of them phase 3. Oxycodone · Pain, Postoperative.

Planned enrollment
Largest of 32
690 · median 126
Started
2024
with 1 other
Phase 4
18 of 32
2 open now
Registered
27th of 32
by date

Among the 32 studies testing oxycodone in Pain, Postoperative, this one has the largest planned enrollment, is one of 2 that started in 2024, is one of 18 in phase 4, and was the 27th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 32 studies testing oxycodone in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing oxycodone in Pain, Postoperative, or all of them as a file.
02

Study summary

POPCORN trial will compare the side effects and effectiveness of Morphine versus Oxycodone medication when prescribed for use as patient controlled analgesia (PCA) for pain relief for paediatric patients after-surgery. This trial is embedded into routine patient care using the hospital electronic medical record (EMR). Participants will be randomly assigned to either medication after they enrol in the study.

The main questions the POPCORN trial aims to answer are:

  • 1. Is there a difference in the usage of medication to treat nausea and vomiting for those who received oxycodone PCA versus morphine PCA for post-surgery pain relief?
  • 2. Is there a difference in side effects or pain relief needed between the two groups?

Study activities are as follows:

  • Participants enrolled to study during their pre-operative consultation
  • Participants are randomly assigned to morphine or oxycodone
  • No further study-specific activities expected from participant after enrolment and randomisation
  • Participant receives routine medical care as planned
  • Clinicians record assessments as per routine care in electronic medical record (EMR)
  • EMR data are extracted as trial data
Read the detailed description

Morphine and oxycodone are commonly used intravenous (IV) opioids in adult and paediatric post-operative patients. Traditionally, morphine has been preferentially prescribed with PCA. However, IV oxycodone is rapidly becoming more popular. Despite systematic reviews describing their use within the adult population, very little is known about the comparative side-effect profiles of morphine versus oxycodone within the paediatric post-operative population. Both options are currently in use and considered standard of care at The Royal Children's Hospital (RCH), Melbourne, Australia. However, there is limited literature to support a clinician's choice between IV oxycodone PCA versus IV morphine PCA.

The aim of this embedded randomized controlled trial is to compare the side-effect profile of IV oxycodone PCA to IV morphine PCA in post-operative paediatric patients.

This is a single site, randomised, embedded trial with two intervention arms, namely IV morphine PCA and IV oxycodone PCA. The study will not be blinded due to the need for opioid syringes to be readily identifiable on the ward. Apart from the consent and randomisation process, there will be no change to current pre-existing practices around PCA use and patient care. Adopting a health informatics approach; patient identification, consent, randomization and reporting of outcomes will be embedded within the EMR.

The primary objective is to compare antiemetic use between the two intervention arms. The secondary objectives will be a comparison of PCA side effects, efficacy and opioid use between the two arms. Outcome data must be what is already recorded as part of usual clinical care within the EMR including: antiemetic administration, respiratory depression (new oxygen and/or high dose naloxone use), urinary retention (need for in-dwelling catheter insertion), constipation (medication laxative administration), itch (RCH Itch Score (0-4 Likert scale)), nausea and vomiting, sedation (0-4 University of Michigan Scoring System), pain (Wong-Baker FACES Pain Rating Scale/Visual Analogue Scale (VAS 0-10) and total opioid consumption (mg/kg/day).

03

Conditions studied

  • Patient-Controlled Analgesia

Browse trials for

Keywords

  • Post-operative Pain
  • Paediatric
  • Patient-controlled analgesia
  • Paediatric analgesia
  • Post-operative
  • Embedded clinical trials
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Postoperative patients who are appropriate for a PCA including those aged 6 and above and up to age 18 years.
  • Those deemed appropriate for either morphine or oxycodone by their treating anaesthetist.
  • American Society of Anaesthesiologists (ASA) score 1-3 inclusive
  • Those whose parents or legal guardians have provided on the patient's behalf.

Exclusion criteria

Exclusion Criteria:

  • Any patients with an allergy, , or to morphine or oxycodone.
  • Patients in the age group with significant intellectual disability or physical incapacity rendering them incapable of using the PCA device
  • 4 or above
  • Inability or unwillingness of parent or legal guardian to provide for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
690 participants (estimated)

Study arms

  • Active comparator
    Intravenous (IV) Morphine Patient controlled analgesia (PCA)

    Morphine PCA IV 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout- as per current RCH Children's Pain Management Service (CPMS) dosing and use.

    Drug: Morphine

  • Active comparator
    IV Oxycodone PCA

    Oxycodone PCA IV 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout- as per current RCH Children's Pain Management Service (CPMS) dosing and use.

    Drug: Oxycodone

Interventions

  • Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout

  • Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout

    Also known as: Oxycodone Juno, Oxycodone HCI Medsurge

06

What researchers measure

Primary outcomes

  1. Antiemetic use

    Prescription incidence and administration of any of the following to participant: Granisetron, Ondansetron, Droperidol, Metoclopramide, Cyclizine, Dexamethasone, and Promethazine

    Time frame: From PCA attachment to 72 hours or 4 hours after ceasing PCA, whichever is first.

Secondary outcomes

  1. Incidence of Respiratory Depression

    Measured as any new oxygen and/or high dose naloxone use (10mcg/kg to max of 400mcg). This will exclude administration of low dose naloxone when used to manage incidence of itch.

    Time frame: The time at which the PCA is first attached to the child and either up to 72 hours or 4 hours after ceasing PCA, whichever is first.

  2. Incidence of Urinary Retention

    Indicated by need for an in-dwelling catheter (IDC) insertion

    Time frame: From PCA attachment to 72 hours or 4 hours after ceasing PCA, whichever is first.

  3. Reports of Itch

    Measured using RCH Itch Score (0-4 Likert scale) where a higher score indicates worse pruritus/itch. 0=comfortable, no itch, 1=itches a little, doesn't interfere with activity, 2= itches more, sometimes interferes with activity, 3= itches a lot, difficult to be still/concentrate, 4= itches most terribly, impossible to sit still/concentrate

    Time frame: From PCA attachment to 72 hours or 4 hours after ceasing PCA, whichever is first.

  4. Reports of Nausea

    Measured via 0-10 visual analogue scale (VAS) scale Nausea will be measured using the nausea scale (0-10 Baxter Retching Faces scale / VAS)

    Time frame: From PCA attachment to 72 hours or 4 hours after ceasing PCA, whichever is first.

  5. Sedation levels

    Measured via University of Michigan Scoring System (0-4 scale) where a higher score indicates higher sedation level. 0= awake and alert, 1= minimally sedated, 2=moderately sedated, 3=deep sedation, 4=unrousable

    Time frame: From PCA attachment to 72 hours or 4 hours after ceasing PCA, whichever is first.

  6. Incidence of Constipation

    Recorded laxative administered is indicative. Medication laxatives only, no food laxatives.

    Time frame: From PCA attachment to 72 hours or 4 hours after ceasing PCA, whichever is first.

  7. Reported pain levels

    Measured via Wong-Baker FACES Pain Rating Scale or Visual Analogue Scale (0-10) higher is more pain. If both a pain scale and a rating are reported but don't align the higher of the two will be used.

    Time frame: From PCA attachment to 72 hours or 4 hours after ceasing PCA, whichever is first.

  8. Total opioid consumption

    All opioids administered, including any background infusions are accurately documented in the EMR. Total opioid administered will be calculated from the EMR. The total morphine equivalent dose will be calculated.

    Time frame: From PCA attachment to 72 hours or 4 hours after ceasing PCA, whichever is first.

  9. Incidence of Vomiting

    Incidence of vomiting will be measured using the documentation of number of vomiting episodes. This will be reported for each day over the study period.

    Time frame: From PCA attachment to 72 hours or 4 hours after ceasing PCA, whichever is first.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Beginning 12 months following analysis and article publication, the following will be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by the Murdoch Children's Research Institute's (MCRI's) independent data use review committee (not including trial sponsor-investigator) and who accept MCRI's conditions, under a collaborator agreement, for accessing participant data after de-identification (text, tables, figures, and appendices) that underlies reported results, along with trial protocol, Statistical Analysis Plan (SAP) and Participant Information and Consent Forms (PICF).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: 12 months following analysis and publication of the primary outcome

Access criteria: Requests for access to previously published anonymised datasets by the scientific community will be reviewed and determined by an independent committee within the MCRI and in accordance with institute policy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 45 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2023
First posted
Dec 29, 2023
StartActual
Mar 13, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06186141
Lead sponsor
Murdoch Childrens Research Institute
Responsible party
Sponsor
First posted
Dec 29, 2023
Start date
Mar 13, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Justine Adams
Contact
justine.adams@mcri.edu.au
03 8341 6200
Suzette Sheppard
Contact
Suzette.sheppard@mcri.edu.au
03 9345 4901
Sue May Koh
principal investigator · Murdoch Childrens Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion